Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro is the slimming jab most prescribed for weight management in the UK right now. It contains tirzepatide, a medicine that acts on two appetite-regulating pathways in the body, and in clinical trials participants lost an average of around 20% of body weight at the highest dose over 72 weeks. It is a prescription-only medicine, so a clinician must assess your suitability before you can start. Here is what the process actually looks like, step by step.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro's active ingredient, tirzepatide, mimics two gut hormones that your body releases after eating: GLP-1 and GIP. Together they signal to the brain that you are full, slow the rate at which your stomach empties and help regulate blood sugar. The result, for most people, is a noticeably reduced appetite and a natural tendency to eat less at each meal.
That dual action sets it apart from older injections that target only GLP-1. You can read more about the mechanism on the tirzepatide overview page, but the practical effect is straightforward: less hunger, smaller portions, steadier energy. The NHS medicines page for tirzepatide covers how it works, common side effects and what to tell your doctor before starting, and is worth a read before your consultation.
One thing worth checking before you go any further: look up any online pharmacy you are considering on the GPhC register. It takes under a minute and confirms the pharmacy is legitimately registered. This single step rules out the vast majority of counterfeit sellers.
As a prescription medicine, Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above if you have at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. A BMI figure alone does not determine approval — the prescriber considers your full medical history, current medicines and any conditions that could affect safety.
NICE recommended tirzepatide for NHS use in December 2024, but the NHS criteria are stricter and phased, so many people who qualify under the licensed terms do not yet meet NHS thresholds. If that describes your situation, our weight-loss treatment overview explains the private and NHS routes side by side. A full eligibility assessment is part of every consultation at our pharmacy, reviewed personally by a GPhC-registered prescriber.
For people researching costs alongside eligibility, the context around Mounjaro's UK pricing is worth understanding before comparing providers.
The headline figure from SURMOUNT-1, the phase 3 trial published in the New England Journal of Medicine, was an average body-weight reduction of around 20 to 21% at the 15 mg dose over 72 weeks, in adults with obesity and no diabetes. A later head-to-head study, SURMOUNT-5, found tirzepatide produced greater average weight loss than semaglutide 2.4 mg over the same period. These results come from randomised controlled trials alongside a reduced-calorie diet and increased activity — not standalone. Real-world results vary.
The trial programme involved thousands of adults across multiple studies. The SURMOUNT-1 trial alone randomised 2,539 participants, and the broader tirzepatide programme across SURPASS and SURMOUNT combined more than 10,000 participants in total. That scale informs the confidence behind NICE's recommendation. More detail on the Mounjaro treatment page covers the evidence in full.
The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and burping. These tend to be most noticeable when you begin or after a dose increase, and for many people they settle within a week or two. If you are considering using Mounjaro as a slimming jab, starting at the lowest dose exists precisely to give your body time to adjust rather than jumping straight to a therapeutic level.
Rare but serious effects include acute pancreatitis. The MHRA issued a Drug Safety Update for GLP-1 medicines in January 2026 specifically on this: seek urgent medical help for severe stomach pain that radiates to the back, especially if accompanied by vomiting. You can report any suspected side effect, and flag suspect sellers, via the Yellow Card scheme. A fuller picture of Mounjaro's side effects is on the dedicated page, and our prescribers review your personal risk profile before any treatment begins, including for those coming to us through slimming direct with Mounjaro. If you have questions between appointments, our team is reachable through the support page seven days a week.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.